stockrow
Friday 6 November 2026
Export PTPI’s income statement to Excel — free account
Petros Pharmaceuticals, Inc.
PTPI Healthcare Drug Manufacturers Specialty & Generic
Petros Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $5.1 million, down 12.2% from fiscal 2023.
- Revenue
- +299.1%
- EPS
- +75.0%
- Free cash flow
- +71.3%
Quarter to June 2026, against a year earlier
0.00
0.00
NaN
Follow PTPI
Alert me
Petros Pharmaceuticals, Inc. (PTPI) P/E ratio
Petros Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (June 2026) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PTPI Petros Pharmaceuticals, Inc. | n/m |
| SBFM Sunshine Biopharma, Inc. compare | n/m |
| SXTC China SXT Pharmaceuticals, Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)